Metafolin® is L-methylfolate, the active form of folate that predominantly occurs in foods and is directly bioavailable. Folic acid, in comparison, needs to be activated before it can be used by the body. The efficacy of these metabolic processes shows high individual fluctuations, which means it is possible that folic acid will not be adequately converted into metabolically active folate forms by some individuals. Metafolin® can be directly used by the body – independent of the underlying genotype of specific folate dependent enzymes (e.g., MTHFR: methylenetetrahydrofolate reductase).
Meeting regulatory requirements
In 2001, the U.S. FDA accepted our new dietary ingredient notification. Metafolin® is approved in key regions and for product categories. Metafolin® is also known as L-methylfolate; L-5-MTHF-Ca; L-methylfolate calcium; L-5-Methyltetrahydrofolic acid, calcium salt; [6S]-5-Methyltetrahydrofolic acid, calcium salt.
Metafolin® is protected by a comprehensive set of patents and patent applications on the substance, key intermediates, production processes and its use in specific fields. Therefore Metafolin® can be licensed to selected companies in clearly-defined market segments.
For more information regarding Metafolin®, please contact us.
Botto L & Yang Q. (2000). 5,10-Methylenetetrahydrofolate reductase gene variants and congenital anomalies: A HuGE Review. Am J Epidemiol. 151(9):862-77.
Gutstein S, et al. (1973). Failure of response to N5-methyltetrahydrofolate in combined folate and B12 deficiency. Evidence in support of the “folate trap” hypothesis. Am J Dig Dis. 18(2):142-6.
Hasselwander O, et al. (2000): 5-Methyltetrahydrofolate: The active form of folic acid. Functional foods 2000, Conference proceedings.
Herbert V & Zalusky R. (1962). Interrelations of vitamin B12 and folic acid metabolism: folic acid clearance studies. J Clin Invest. 41:1263-76.
Kelly P, et al. (1997). Unmetabolized folic acid in serum: acute studies in subjects consuming fortified food and supplements. Am J Clin Nutr. 65(6):1790-5.
Kirke P, et al. (2004). Impact of the MTHFR C677T polymorphism on risk of neutral tube defects: case-control study. BMJ. 328(7455):1535-6.
Lamers Y, et al. (2004). Supplementation with [6S]-5-methyltetrahydrofolate or folic acid equally reduces plasma total homocysteine concentrations in healthy women. Am J Clin Nutr. 79(3):473-8.
Levitt M, et al. (1971). Transport characteristics of folates in cerebrospinal fluid; a study utilizing doubly labeled 5-methyltetrahydrofolate and 5-formyltetrahydrofolate. J Clin Invest. 50(6):1301-8
Lucock M. (2004). Is folic acid the ultimate functional food component for disease prevention? BMJ. 328(7433):211-4.
Noronha JM & Silverman M. (1962) On folic acid, vitamin B12, methionine and forminoglutamic acid metabolism. In: Vitamin B12 and Intrinsic Factor (ed.by H.C.Heinrich), pp. 728–736. Enke, Stuttgart.
Obeid R, et al. (2011). Concentrations of unmetabolized folic acid and primary folate forms in plasma after folic acid treatment in older adults. Metabolism. 60(5):673-80.
Patanwala I, et al. (2014). Folic acid handling by the human gut: implications for food fortification and supplementation. Am J Clin Nutr. 100(2):593-599.
Scott J. (2001). Methyltetrahydrofolate: The Superior Alternative to Folic acid. Nutraceuticals in health and disease prevention, 75-90 [Krämer K, Hoppe PP and Packer L, editors]. New York: Marcel Dekker Inc.
Spector R & Lorenzo AV. (1975). Folate transport in the central nervous system. Am J Physiol. 229(3):777-82.
Sweeney M et al. (2005). Evidence of unmetabolised folic acid in cord blood of newborn and serum of 4-day-old infants. Br J Nutr. 94(5):727-30.
Troen A, et al. (2006). Unmetabolized folic acid is associated with reduced natural killer cell cytotoxicity among postmenopausal women. J Nutr.136(1):189-94.
Venn BJ, et al. (2003). Comparison of the effect of low-dose supplementation with L-5-methyltetrahydrofolate or folic acid on plasma homocysteine: a randomized placebo-controlled study. Am J Clin Nutr. 77(3): 658-62.